Neuromonics
What You Should Know
About Neuromonics Tinnitus Treatment
The Neuromonics Tinnitus Treatment is an FDA-cleared, non-invasive approach
that may provide a significant long-term reduction in tinnitus disturbance.
Tinnitus can be a debilitating condition often characterized by a constant
ringing in the ears. The treatment is designed to interact, interrupt and desensitize
tinnitus disturbance, changing how the brain perceives the tinnitus sounds.
It is the most comprehensive long-term therapy that targets the audiological,
neurological and psychological basis of the condition.
The Neuromonics Tinnitus Treatment is delivered via a compact, lightweight
and specially-designed medical device. Using a highly sophisticated and patented
algorithm, the Neuromonics Tinnitus Treatment is customized to the individual
patient’s unique hearing and tinnitus profile. It sends particular auditory
stimulation across a broad range of frequencies, including high frequencies
most critical for tinnitus treatment. The Neuromonics Tinnitus Treatment introduces
and delivers both continuous and intermittent pre-programmed stimuli, which
is coordinated with precisely-designed music.
The stimulus targets the brain’s auditory pathways and aids in neuroplasticity,
or establishing new neural connections. The Neuromonics Tinnitus Treatment
leverages recent scientific findings that the brain is not hard-wired with
fixed neurological circuits. By enabling new neural connections, the Neuromonics
Tinnitus Treatment helps sufferers filter out the tinnitus sound for long-term
benefit. Additionally, the music engages the brain’s limbic system, the
part of the brain associated with emotional response, allowing for effective
stimulus delivery and treatment.
Prior to treatment, the patient’s tinnitus and hearing is evaluated to
determine his or her personal audiological profile. If the patient is an appropriate
candidate, delivery and fitting of the customized Neuromonics device takes
place with the physician or audiologist.
Treatment occurs over a six-month period and is administered by an audiologist
or physician. It involves two stages:
- Stage One: treatment offers relief from tinnitus symptoms, by delivering
an acoustic neural stimulus that provides a high level of interaction
with tinnitus perception. The stage lasts approximately two months.
- Stage Two: the acoustic neural stimulus changes to deliver an intermittent
or lower level of interaction with the patient’s tinnitus perception.
This allows desensitization to occur. The stage lasts approximately four
months.
About Neuromonics
Neuromonics is the manufacturer and distributor of the only FDA-cleared, patented,
customized and clinically-proven medical device designed for long-term significant
relief of tinnitus. With more than fourteen years of research and development,
the Neuromonics Tinnitus Treatment has treated thousands of tinnitus sufferers
worldwide. The goal of Neuromonics is to help tinnitus sufferers improve their
quality of life and overcome challenges associated with tinnitus.
Founded in 2001, Neuromonics developed a breakthrough medical device for
the treatment of tinnitus. The Neuromonics Tinnitus Treatment was discovered
and developed at Western Australia’s Curtin University of Technology
by Dr. Paul Davis. The uniquely patented device and the associated treatment
has been through extensive refinement through ongoing research and multiple
clinical trials. The product, originally launched in Australia in 2004, has
shown widespread acceptance and validation with thousands of patients having
completed treatment. In late 2005, the product was launched in a few select
clinics in the United States. With continued validation of the effectiveness
of the treatment, business in the United States has seen rapid growth with
expansion plans in the next few years to include both Europe and Asia.
Clinical Outcomes
(after 6 months of treatment*):
- 40% + Reduction in Tinnitus Disturbance**………………….…95%
- 40% + Reduction in Tinnitus Awareness…………….…………84%
- 5dB + Reduction in Minimum Masking Level***……………..…78%
- 5dB + Improvement in Loudness Discomfort Levels****…..….69%
*Clinical measures reported by participants with significant levels
of tinnitus disturbance prior to treatment.
**Measured by the Tinnitus Reaction Questionnaire
***Participants with pretreatment minimum masking level of greater
than 5dB
****Participants with decreased sound tolerance
Patient Satisfaction
- Relief from Tinnitus ……………………..……….97%
- Improved ability to fall Asleep …………......….…94%
- A Sense of Control of Tinnitus ……….........…….94%
- Improved ability to Relax ……………..…...…….94%
Davis, P., Paki, B., Hanley, P. Neuromonics Tinnitus Treatment: Third Clinical
Trial. Ear and Hearing. 2007; Vol. 28, No. 2; 242-257.
|
